BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Week In Review | Sep 27, 2019
Company News

FDA broadens approval for Exact's Cologuard

FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and older. The non-invasive home-based stool test was marketed for average-risk adults 50 and older. Exact is working...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
BC Extra | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

Locana Inc. (San Diego, Calif.) hired Kathie Bishop as CSO to succeed acting CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc. (NASDAQ:OTIC) and previously held roles...
BC Extra | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion. The deal also helps accelerate a...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | May 30, 2019
Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
BioCentury | Oct 12, 2018
Finance

A Glympse at drug response

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its sensors to both diagnostics and drug response monitoring. Polaris Partners and Arch Venture Partners co-led the...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Company News

Exact enlists Pfizer to boost Cologuard sales

Exact Sciences Corp. (NASDAQ:EXAS) gained $15.27 (31%) to $65.32 on Aug. 22 after partnering with Pfizer Inc. (NYSE:PFE) to co-promote Exact's Cologuard in the U.S. Exact hopes the partnership will drive adoption of the non-invasive...
Items per page:
1 - 10 of 236
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Week In Review | Sep 27, 2019
Company News

FDA broadens approval for Exact's Cologuard

FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and older. The non-invasive home-based stool test was marketed for average-risk adults 50 and older. Exact is working...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
BC Extra | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

Locana Inc. (San Diego, Calif.) hired Kathie Bishop as CSO to succeed acting CSO Gene Yeo, who co-founded the company and chairs its SAB. Bishop was CSO at Otonomy Inc. (NASDAQ:OTIC) and previously held roles...
BC Extra | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion. The deal also helps accelerate a...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | May 30, 2019
Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
BioCentury | Oct 12, 2018
Finance

A Glympse at drug response

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its sensors to both diagnostics and drug response monitoring. Polaris Partners and Arch Venture Partners co-led the...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BC Week In Review | Aug 31, 2018
Company News

Exact enlists Pfizer to boost Cologuard sales

Exact Sciences Corp. (NASDAQ:EXAS) gained $15.27 (31%) to $65.32 on Aug. 22 after partnering with Pfizer Inc. (NYSE:PFE) to co-promote Exact's Cologuard in the U.S. Exact hopes the partnership will drive adoption of the non-invasive...
Items per page:
1 - 10 of 236